Correspondingly, there is strong evidence that suggests that HER2-positive (HER2+) breast cancers are more aggressive than HER2-negative (HER2-) breast cancers, leading to poorer patient prognosis and unfavourable tumour characteristics [3, 8, 9]. The gene discussed is ERBB2; the disease is neoplasm.